Pimavanserin: A novel therapeutic option for Parkinson disease psychosis

In the Review article “Pimavanserin: A novel therapeutic option for Parkinson disease psychosis” by T. Hawkins and B.D. Berman,¹ there are 2 minor errors. The last sentence in the third paragraph under “Development of pimavanserin” should have read “In addition, pimavanserin did not affect motor symptom severity and led to significant decreases in caregiver burden and improvements in nighttime sleep and daytime wakefulness.” The second-to-last sentence under “Prescribing information” should read “In the positive phase 3 trial of pimavanserin detailed above, there were 3 deaths; 2 in the treatment group and 1 in the placebo group.” The authors regret the errors.